Caseware UK (AP4) 2023.0.135 2023.0.135 2023-12-312023-12-312023-01-01No description of principal activityfalse00truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 09547901 2023-01-01 2023-12-31 09547901 2022-01-01 2022-12-31 09547901 2023-12-31 09547901 2022-12-31 09547901 c:Director1 2023-01-01 2023-12-31 09547901 d:CurrentFinancialInstruments 2023-12-31 09547901 d:CurrentFinancialInstruments 2022-12-31 09547901 d:Non-currentFinancialInstruments 2023-12-31 09547901 d:Non-currentFinancialInstruments 2022-12-31 09547901 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 09547901 d:CurrentFinancialInstruments d:WithinOneYear 2022-12-31 09547901 d:Non-currentFinancialInstruments d:AfterOneYear 2023-12-31 09547901 d:Non-currentFinancialInstruments d:AfterOneYear 2022-12-31 09547901 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2023-12-31 09547901 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2022-12-31 09547901 d:Non-currentFinancialInstruments d:MoreThanFiveYears 2023-12-31 09547901 d:Non-currentFinancialInstruments d:MoreThanFiveYears 2022-12-31 09547901 d:ShareCapital 2023-12-31 09547901 d:ShareCapital 2022-12-31 09547901 d:SharePremium 2023-12-31 09547901 d:SharePremium 2022-12-31 09547901 d:RetainedEarningsAccumulatedLosses 2023-12-31 09547901 d:RetainedEarningsAccumulatedLosses 2022-12-31 09547901 c:FRS102 2023-01-01 2023-12-31 09547901 c:AuditExempt-NoAccountantsReport 2023-01-01 2023-12-31 09547901 c:FullAccounts 2023-01-01 2023-12-31 09547901 c:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 09547901 6 2023-01-01 2023-12-31 09547901 e:PoundSterling 2023-01-01 2023-12-31 iso4217:GBP xbrli:pure

Registered number: 09547901









BIOKEMIX WORLDWIDE LTD







UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

 
BIOKEMIX WORLDWIDE LTD
REGISTERED NUMBER: 09547901

BALANCE SHEET
AS AT 31 DECEMBER 2023

2023
2022
Note
£
£

Fixed assets
  

Investments
 4 
1,337,398
1,324,444

  
1,337,398
1,324,444

Current assets
  

Debtors: amounts falling due within one year
 5 
418,719
206,138

Cash at bank and in hand
 6 
1,075
952

  
419,794
207,090

Creditors: amounts falling due within one year
 7 
(577,883)
(413,872)

Net current liabilities
  
 
 
(158,089)
 
 
(206,782)

Total assets less current liabilities
  
1,179,309
1,117,662

Creditors: amounts falling due after more than one year
 8 
(1,107,393)
(1,025,736)

  

Net assets
  
71,916
91,926


Capital and reserves
  

Called up share capital 
  
1,125
1,125

Share premium account
  
166,077
166,077

Profit and loss account
  
(95,286)
(75,276)

  
71,916
91,926


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 

Page 1

 
BIOKEMIX WORLDWIDE LTD
REGISTERED NUMBER: 09547901
    
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2023




................................................
Sameer Bajaj
Director

Date: 19 March 2025

The notes on pages 3 to 7 form part of these financial statements.

Page 2

 
BIOKEMIX WORLDWIDE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1.


General information

Biokemix Worldwide Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address are as below:
Registered number: 09547901
Registered office: 1 Doughty Street, London, United Kingdom, WC1N 2PH.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of comprehensive income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

 
2.3

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.4

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

Page 3

 
BIOKEMIX WORLDWIDE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.5

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of comprehensive income for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in profit or loss for the period.

 
2.6

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.7

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.8

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees




The Company has no employees other than the directors, who did not receive any remuneration (2022 - £NIL).

The average monthly number of employees, including directors, during the year was 0 (2022 - 0).

Page 4

 
BIOKEMIX WORLDWIDE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

4.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


At 1 January 2023
1,324,444


Additions
12,954



At 31 December 2023
1,337,398





5.


Debtors

2023
2022
£
£


Amounts owed by group undertakings
417,419
204,838

Other debtors
1,300
1,300

418,719
206,138



6.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
1,075
952

1,075
952


Page 5

 
BIOKEMIX WORLDWIDE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

7.


Creditors: Amounts falling due within one year

2023
2022
£
£

Other loans
-
15,714

Trade creditors
13,530
13,530

Amounts owed to group undertakings
501,986
354,286

Other creditors
45,253
13,728

Accruals and deferred income
17,114
16,614

577,883
413,872



8.


Creditors: Amounts falling due after more than one year

2023
2022
£
£

Bank loans
33,517
38,032

Other loans
1,073,876
987,704

1,107,393
1,025,736


Page 6

 
BIOKEMIX WORLDWIDE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

9.


Loans


Analysis of the maturity of loans is given below:


2023
2022
£
£

Amounts falling due within one year

Other loans
-
15,714


-
15,714


Amounts falling due 2-5 years

Other loans
1,073,876
987,704


1,073,876
987,704

Amounts falling due after more than 5 years

Bank loans
33,517
38,032

33,517
38,032

1,107,393
1,041,450



10.


Controlling party

Auric SKB Ltd (Company No. 11985640) is ultimate parent company of the group. Its registered office address is 14 Old Queen Street, London, England, SW1H 9HP.

 
Page 7